Sharekhan

Thyrocare Technologies Ltd

Fri 6/06/2025,15:57:50 NSE: THYROCARE

₹ 952.80 -43.90 (-4.40%)
BUY NOW Buy Thyrocare Technologies Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Thyrocare Technologies Ltd

Fri 6/06/2025,16:1:0

Thyrocare Technologies Ltd

Fri 6/06/2025,15:57:50 | NSE : THYROCARE

₹ 952.80-43.90 (-4.40%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 983.00

Previous Close

₹ 996.70

Volume

203449

Mkt Cap ( Rs. Cr)

₹5049.31

High

₹ 995.50

Low

₹ 874.10

52 Week High

₹ 1073.20

52 Week Low

₹ 572.00

Book Value Per Share

₹ 92.12

Dividend Yield

2.09

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Thyrocare Technologies Ltd

Your Vote -

Buy

81.25%

Hold

8.33%

Sell

10.42%

81.25%

48 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

64%

Sell Order Quantity

36%

Bid Price

Qty

973.30

27

973.00

2

973.00

15

973.00

20

973.00

32

Bid Total

20134

Bid Price

Qty

973.90

29

974.00

35

974.00

1

974.00

4

974.00

2

Bid Total

11237

Option Chain

Analyzes market sentiment, predicts Thyrocare Technologies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Acquisition

    3 Jun 2025, 8:40PM Please find attached herewith Disclosure under Regulation 30 for additional Capital Infusion in Thyrocare Laboratories (Tanzania) Limited

  • Thyrocare Tech. - General Updates

    3 Jun 2025, 8:39PM Thyrocare Technologies Limited has informed the Exchange about additional Capital infusion in Thyrocare Laboratories (Tanzania) Limited.

  • Thyrocare Tech. - Alteration Of Capital and Fund Raising-XBRL

    21 May 2025, 11:55AM Thyrocare Technologies Limited has informed the Exchange regarding Allotment of Securities

  • Thyrocare Tech. - ESOP/ESOS/ESPS

    21 May 2025, 11:39AM Thyrocare Technologies Limited has informed the Exchange regarding Allotment of 996 Shares.

  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    21 May 2025, 11:41AM Attached is herewith Intimation for Allotment of Equity Shares in view of the exercise of Stock Options

  • Thyrocare Tech. - Disclosure under SEBI Takeover Regulations

    9 May 2025, 5:37PM Docon Technologies Private Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of I

  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    29 Apr 2025, 2:04PM Please find attached herewith Transcript for conference call held on April 23, 2022.

  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    29 Apr 2025, 2:00PM Thyrocare Technologies Limited has informed the Exchange about Transcript

  • Thyrocare Tech. - Copy of Newspaper Publication

    24 Apr 2025, 4:16PM Thyrocare Technologies Limited has informed the Exchange about Copy of Newspaper Publication of Audited financial results for the quarter and year end

  • Thyrocare Tech. - Outcome of Board Meeting-XBRL

    23 Apr 2025, 9:38PM Thyrocare Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on 23-Apr-2025 for Dividend

  • Thyrocare Tech. - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    23 Apr 2025, 9:33PM THYROCARE TECHNOLOGIES LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Trans

  • Thyrocare Tech. - Audio Recordings Of Earnings Conference Call For The Quarter And Year Ended March 31, 2025.

    23 Apr 2025, 8:56PM Please find attached herewith link for Audio recordings for Earnings Conference call for the Quarter and year ended March 31, 2025.

  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Apr 2025, 8:48PM Thyrocare Technologies Limited has informed the Exchange about Link of Recording

  • Thyrocare Tech. - Updates

    23 Apr 2025, 4:46PM Thyrocare Technologies Limited has informed the Exchange regarding 'Appointment of Secretarial Auditors and Re-appointment of Cost Auditor'.

  • Thyrocare Tech. - Investor Presentation

    23 Apr 2025, 4:36PM Thyrocare Technologies Limited has informed the Exchange about Investor Presentation

  • Thyrocare Tech. - Press Release

    23 Apr 2025, 4:32PM Thyrocare Technologies Limited has informed the Exchange regarding a press release dated April 23, 2025, titled ""On Audited Financial Results for Qua

  • Thyrocare Tech. - Dividend

    23 Apr 2025, 4:25PM Thyrocare Technologies Limited has informed the Exchange that Board of Directors at its meeting held on April 23, 2025, recommended Final Dividend of

  • Thyrocare Tech. - Outcome of Board Meeting

    23 Apr 2025, 4:15PM Thyrocare Technologies Limited has informed the Exchange regarding Outcome of Board Meeting held on April 23, 2025.

  • Thyrocare Tech. - Appointment Of Secretarial Auditors And Re-Appointment Of Cost Auditor

    23 Apr 2025, 4:47PM Please find attached herewith Intimation herewith for the appointment of Secretarial Auditors and re-appointment of Cost Auditor.

  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Investor Presentation

    23 Apr 2025, 4:38PM Attached herewith Investor Presentation on Audited Financial Results (Standalone and Consolidated) for the Quarter and year ended March 31, 2025.

  • Thyrocare Tech. - Announcement under Regulation 30 (LODR)-Dividend Updates

    23 Apr 2025, 4:27PM The Board of Directors in their Meeting held on April 23, 2025, have recommended the Final Dividend of Rs 21 per Equity Share. Please find attached Ou

  • Thyrocare Tech. - Financial Results For Quarter And Year Ended March 31, 2025 And Recommendation Of Final Dividend

    23 Apr 2025, 4:24PM please find attached herewith Audited Standalone and Consolidated Financial Results for Quarter and year ended March 31, 2025.

  • Thyrocare Tech. Q4 net profit up 14.14% at Rs 21.95 cr

    23 Apr 2025, 4:20PM The company reported standalone net profit of Rs 21.95 crore for the quarter ended March 31, 2025 as compared to Rs 19.23 crore in the same period las

  • Thyrocare Tech. - Board Meeting Outcome for Outcome Of Board Meeting Held On April 23, 2025

    23 Apr 2025, 4:10PM Outcome of Board Meeting held on April 23, 2025

  • Thyrocare Tech. - Board Meeting Intimation

    16 Apr 2025, 11:11AM THYROCARE TECHNOLOGIES LIMITED has informed the Exchange about Board Meeting to be held on 23-Apr-2025 to consider and approve the Yearly Audited Fina

  • Thyrocare Tech. has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    15 Apr 2025, 10:00PM As of March 2025, 71.06% is owned by Indian Promoters and 28.94% by Public. <p align=justify> Institutional holds 17.38% (Insurance Companies 1.06%) a

  • Thyrocare Tech. - Analysts/Institutional Investor Meet/Con. Call Updates

    15 Apr 2025, 9:34PM Thyrocare Technologies Limited has informed the Exchange about Invite for Earnings Conference Call.

  • Thyrocare Tech. - Board Meeting Intimation for Consideration And Approval Of Audited Standalone And Consolidated Financial Re

    15 Apr 2025, 9:26PM Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/04/2025 ,inter alia, to consid

  • Thyrocare Tech. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    8 Apr 2025, 8:17PM Please find attached Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the Quarter ended Mar

  • Thyrocare Tech. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    8 Apr 2025, 8:17PM Thyrocare Technologies Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

  • Thyrocare Tech. - Trading Window-XBRL

    27 Mar 2025, 5:37PM Thyrocare Technologies Limited has informed the Exchange about Closure of Trading Window

  • Thyrocare Tech. - Trading Window

    27 Mar 2025, 5:25PM Thyrocare Technologies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regula

  • Thyrocare Tech. - Reply to Clarification- Financial results

    13 Mar 2025, 10:32AM The Exchange had sought clarification from Thyrocare Technologies Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI

  • Thyrocare to acquire Vimta's Diagnostic & Pathological svcs business on a slump sale basis

    30 Aug 2024 , 12:00PM Thyrocare Technologies enters into a BTA to acquire diagnostic and pathological services business of Vimta Labs

  • Thyrocare Technologies

    28 Jun 2021 , 9:32AM The promoters and promoters group of the company have entered in to an agreement with Docon Technologies Private Limited (along with API Holdings Pvt Limited – Persons acting in concert) to sell their entire stake of 66.14% representing 3,49,72,999 equity shares in Thyrocare Technologies for a consideration of 4564 crs, translating to RS 1305 per equity share. Consequent to the execution of share purchase agreement, an open offer for acquisition of 1.37 crore shares of Thyrocare, representing 26% of the expanded voting share capital has been announced at a price of Rs 1300 per share, which is at a discount of 10.2% as compared to closing price of Rs 1448 as on 25th June 2021.

  • Thyrocare board approves share buyback

    10 Sep 2018 , 11:56AM Thyrocare Technologies board approved buyback of 8.63 lakh shares at Rs. 730 per share (14% upside from closing on Sep 07,2018) aggregating to Rs. 63 crores; The buyback size is 14.97% of the aggregate paid-up share capital –Positive for Thyrocare; buyback is open only for public shareholders (promoters not allowed); Objective of buyback is to return surplus cash to shareholders.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Thyrocare Technologies Ltd stock 

Name March-25 March-24 March-23 March-22 March-21
Assets 537.1 533.58 521.04 520.7 445.46
Liabilities 537.1 533.58 521.04 520.7 445.46
Equity 52.99 52.95 52.93 52.9 52.87
Gross Profit 187.02 133.88 112.01 230.83 170.74
Net Profit 95.78 71.14 56.97 152.05 119.77
Cash From Operating Activities 190.76 155.19 120.02 105.68 110.41
NPM(%) 15.12 13.57 11.71 27.07 25.25
Revenue 633.1 524.02 486.46 561.53 474.27
Expenses 446.08 390.14 374.45 330.7 303.53
ROE(%) 19.61 14.57 11.66 31.14 24.53

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
21 210 2.2 769.2
16 Aug 2024 18 180 2.2 647.25
20 Apr 2023 18 180 2.2 475.9
11 May 2022 15 150 2.2 770.95
17 Jun 2021 15 150 2.2 1063.6
12 Nov 2020 10 100 2.2 1137.65
21 Nov 2019 5 50 2.2 558.55
14 Aug 2019 20 200 2.2 434.7
02 Aug 2018 5 50 2.2 668.95
15 Feb 2018 5 50 2.2 676.2
03 Aug 2017 5 50 2.2 735.45
08 Feb 2017 5 50 2.2 709
01 Sep 2016 2.5 25 2.2 602

Peers

Other companies within the same industry or sector that are comparable to Thyrocare Technologies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 806.20 0.63 26.75 568.67 301.39 0.62
Lotus Eye Hospital and Institute Ltd 70.96 0.58 202.74 2072.14 3.55 0.00
Vaishali Pharma Ltd 12.82 0.00 213.67 1068.06 3.13 0.00
Astec Lifesciences Ltd 810.75 3.71 0.00 1953.85 -687.10 0.00

Company Info

The Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai as a public limited company under the Companies Act, 1956. the Company was issued a certificate of commencement of business from the RoC on March 7, 2000. Major events and milestones of the Company : 2000 -The Company was incorporated in the name and style of "Thyrocare Technologies Limited' and received a certificate for commencement of operations. 2001 -The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005 -The Company received NABL accreditation. 2006 -The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007 -The Company receives accreditation from the College of American Pathologists (CAP). 2010 -The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1,250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011 -The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012 -NVP acquired certain Equity Shares aggregating to 1,200 million from certain entities. 2013 -EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation. 2014 -The Company had installed, India's first and the world's longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations. 2015 -The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception. 2016 -Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. 2024 -Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited.

The Company was incorporated as Thyrocare Technologies Limited on January 28, 2000 at Mumbai as a public limited company under the Companies Act, 1956. the Company was issued a certificate of commencement of business from the RoC on March 7, 2000. Major events and milestones of the Company : 2000 -The Company was incorporated in the name and style of "Thyrocare Technologies Limited' and received a certificate for commencement of operations. 2001 -The Company received ISO 9001 certification. -The Company commenced commercial operations under the brand name 'Thyrocare' pursuant to the acquisition of business of TDPL and TBPL (which were incorporated in 1996). 2005 -The Company received NABL accreditation. 2006 -The Company issued certain fully convertible debentures aggregating to 250 million to BCCL. 2007 -The Company receives accreditation from the College of American Pathologists (CAP). 2010 -The Company issued certain compulsorily convertible debentures aggregating to 250 million to Agalia. Agalia also acquired certain Equity Shares aggregating to 1,250 million from the Promoters and certain other persons. -The Company launched wellness packages under the brand name "Aarogyam". 2011 -The Company migrated to "total laboratory automation system" installed by Siemens for efficient handling of increasing volumes. 2012 -NVP acquired certain Equity Shares aggregating to 1,200 million from certain entities. 2013 -EIF acquired certain Equity Shares from Agalia. -The Subsidiary commenced operations at the PET-CT centres at Navi Mumbai and conducted over 1,000 scans in the first year of operation. 2014 -The Company had installed, India's first and the world's longest track automation system for seamless sample movements from Siemens Limited. -The Company commissioned the operations in medical cyclotron facility in Navi Mumbai. -The Subsidiary commenced operations at the PET-CT centres in New Delhi and Hyderabad and the PET-CT centres at New Delhi conducted over 1,000 scans in the first year of operations. 2015 -The Company opened RPLs in Delhi, Coimbatore, Hyderabad and Kolkata to expand its coverage and volume of tests and samples processed daily. -The Company acquired the equipment for testing of water samples and commenced operating the equipment under the brand name "WHATERS". These tests, at present include physical and chemical testing, elements testing, microbiology testing, pesticide testing and volatile organic compounds testing. -The Subsidiary has completed over 10,000 scans at the PET-CT centres in New Delhi, over 10,000 scans at the PET-CT centres in Navi Mumbai from the date of inception and over 1,000 scans at the PET-CT centres in Hyderabad since inception. 2016 -Thyrocare Technologies are listed and admitted to dealings on the Exchange in the list of 'B' Group Securities. 2024 -Thyrocare Technologies Completed acquisition of Think Health Diagnostic Private Limited.

Read More

Parent Organisation

Thyrocare Technologies Ltd.

Founded

28/01/2000

Managing Director

Mr.Rahul Guha

NSE Symbol

THYROCAREEQ

FAQ

The current price of Thyrocare Technologies Ltd is ₹ 952.80.

The 52-week high for Thyrocare Technologies Ltd is ₹ 995.50 and the 52-week low is ₹ 874.10.

The market capitalization of Thyrocare Technologies Ltd is currently ₹ 5049.31. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Thyrocare Technologies Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Thyrocare Technologies Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Thyrocare Technologies Ltd shares.

The CEO of Thyrocare Technologies Ltd is Mr.Rahul Guha, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT